Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Harnessing the FBXW7 Somatic Mutant R465C for Targeted Protein Degradation.

Journal of the American Chemical Society - 19 Feb 2025

Basu Ananya A, Zhang Chenlu, Rouhimoghadam Milad, Vasudevan Anil, Reitsma Justin M, Zhang Xiaoyu

Abstract excerpt

Targeted protein degradation (TPD) is a pharmacological strategy that eliminates specific proteins from cells by harnessing cellular proteolytic degradation machinery. In proteasome-dependent TPD, expanding the repertoire of E3 ligases compatible with this approach could enhance the applicability of this strategy across various biological contexts. In this study, we discovered that a somatic mutant of FBXW7,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Proteins
Share to F-Box Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to F-Box-WD Repeat-Containing Protein 7

Share to Mutation

Share to Proteasome Endopeptidase Complex

Share to Proteolysis

Share to Ubiquitin-Protein Ligases

Source

Open in PubMed Open full text

Identifiers

PMID: 39913332
DOI: 10.1021/jacs.4c17331
PMCID: PMC11973725

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Harnessing the FBXW7 Somatic Mutant R465C for Targeted Protein Degradation.PMID 39913332Read ↗

Clinical Translation of Targeted Protein DegradersSemantic proximity Read ↗

PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat CancerSemantic proximity Read ↗

New-generation advanced PROTACs as potential therapeutic agents in cancer therapySemantic proximity Read ↗

Breaking Bad Proteins – Discovery Approaches and the Road to Clinic for DegradersSemantic proximity Read ↗

A CRISPR activation screen identifies FBXO22 as an E3 ligase supporting targeted protein degradationSemantic proximity Read ↗

Targeting the Interplay of Proteins through PROTACs for the Management of Cancer and Associated DisordersSemantic proximity Read ↗

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?Semantic proximity Read ↗

Targeted degradation of USP7 in solid cancer cells reveals disparate effects of deubiquitinase inhibition vs. acute protein depletionSemantic proximity Read ↗

Proteolysis‐targeting chimeras in drug development: A safety perspectiveSemantic proximity Read ↗

Assessing the Suitability of Deubiquitylases As Substrates For Targeted Protein DegradationSemantic proximity Read ↗

Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule InhibitorsSemantic proximity Read ↗

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.